Atlas Trials

Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).

Clinical trial NCT05947617 · UNKNOWN

Trial details

NCT number
NCT05947617
Sponsor
Neobiosis, LLC
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Post-Acute COVID-19 SyndromeCognitive ImpairmentNeurological Complication
Start date
2023-10-01
Primary completion
2025-04-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.